Kisunla (donanemab) is approved to be given as an injection via infusion about every four weeks in patients experiencing mild cognitive impairment or mild dementia, according to the FDA.
In phase 3 clinical trials, Kisunla slowed cognitive and functional decline by up to 35% compared to a placebo, according to a news release from Eli Lilly. The drug was also found to reduce participants’ risk of progressing further to the next stage of Alzheimer’s.
The treatment is not meant to be ongoing and can be stopped when the plaques dissipate to a certain level.
“As a physician, I am encouraged by the potential to stop treatment, which could reduce out-of-pocket costs and infusion burden for eligible patients,” Howard Fillit, MD, cofounder and chief science officer at the Alzheimer’s Drug Discovery Foundation said in the release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
